ArticleJournal of the Society for Cardiovascular Angiography & Interventions2025
Microbubble Contrast Agent Use During Invasive Coronary Microvascular Assessment.
Article in Journal of the Society for Cardiovascular Angiography & Interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary microvascular function assessment with invasive Doppler-derived coronary flow reserve (CFR) has challenges related to Doppler signal quality, limiting clinical adoption. We investigated whether the use of ultrasound microbubble contrast agents can improve coronary flow signals and reduce measurement variability during invasive CFR measurement. Methods: Participants underwent assessment of coronary flow velocity using a Doppler sensor-tipped coronary wire. Baseline signal quality was determined by expert clinicians, and signals were categorized into good or poor quality. Doppler quality was then assessed at predetermined time periods after administration of SonoVue (Bracco): baseline, first pass, and subsequent discrete 20-second time periods, following this up to 260 seconds after first pass. For each time period, several parameters were assessed: signal-to-noise ratio, Doppler envelope quality (analyzed by a previously validated artificial intelligence-based score), and the coefficient of variation of tracked flow velocity. Results: Fifteen cases were included. In the group with poor quality baseline Doppler signal (N = 10), signal-to-noise ratio, Doppler envelope quality score, and coefficient of variation significantly improved with microbubble contrast (signal-to-noise ratio: Conclusions: Ultrasound microbubble contrast agents can enhance Doppler signal quality during invasive CFR measurements. These agents could be used to improve the reliability of flow measurements in clinical practice and facilitate the adoption of coronary microvascular assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.